Ayşe Tanatar1, Şerife Gül Karadağ1, Betül Sözeri2, Hafize Emine Sönmez1, Mustafa Çakan1, Yasemin Kendir Demirkol3, Nuray Aktay Ayaz4. 1. Department of Pediatric Rheumatology, Kanuni Sultan Süleyman Research and Training Hospital, University of Health Sciences, Istanbul, Turkey. 2. Department of Pediatric Rheumatology, Ümraniye Research and Training Hospital, University of Health Sciences, Istanbul, Turkey. 3. Department of Pediatric Genetics, Ümraniye Research and Training Hospital, University of Health Sciences, Istanbul, Turkey. 4. Department of Pediatric Rheumatology, Kanuni Sultan Süleyman Research and Training Hospital, University of Health Sciences, Istanbul, Turkey. nurayaktay@gmail.com.
Abstract
OBJECTIVE: To describe the clinical features, genotype, and treatment approaches of patients with confirmed adenosine deaminase 2 (ADA2) deficiency with dissimilar phenotypes. METHODS: A case series of five DADA2 patients from three families was presented. The clinical and laboratory data, treatment protocols, and outcome of the patients were recorded from the patients' medical charts. ADA2 gene was screened by next generation sequencing first and then verified by Sanger sequencing. Serum ADA2 enzyme activity was measured by modified spectrophotometric method. RESULTS: The median (min-max) age at onset of symptoms and age at diagnosis were 11 (9-13.8) years and 15 (9-19) years, respectively. The median (min-max) follow-up period was 8 (6-45) months. There was consanguinity in two families (2/3). The main clinical manifestations are musculoskeletal (5/5), dermatological (4/5), and neurological (2/5). Homozygosity for the p.G47R mutation in ADA2 gene was detected in three patients. A homozygous mutation in ADA2 gene (c.650 T > A; p.Val217Asp) was detected in two siblings. Plasma ADA2 enzymatic activity was absent in all patients. Anti-tumor necrosis factor (TNF) therapy was commenced, and all patients became clinically inactive with normal acute-phase reactants. CONCLUSION: ADA2 mutations should be checked in patients with presence of inflammation and livedoid vasculitis when they have neurological findings, especially in the form of stroke; and a history suggesting for an inherited disease; or presence of resistance to conventional treatment. Besides, anti-TNF seems to be useful for treatment of DADA2.
OBJECTIVE: To describe the clinical features, genotype, and treatment approaches of patients with confirmed adenosine deaminase 2(ADA2) deficiency with dissimilar phenotypes. METHODS: A case series of five DADA2 patients from three families was presented. The clinical and laboratory data, treatment protocols, and outcome of the patients were recorded from the patients' medical charts. ADA2 gene was screened by next generation sequencing first and then verified by Sanger sequencing. Serum ADA2 enzyme activity was measured by modified spectrophotometric method. RESULTS: The median (min-max) age at onset of symptoms and age at diagnosis were 11 (9-13.8) years and 15 (9-19) years, respectively. The median (min-max) follow-up period was 8 (6-45) months. There was consanguinity in two families (2/3). The main clinical manifestations are musculoskeletal (5/5), dermatological (4/5), and neurological (2/5). Homozygosity for the p.G47R mutation in ADA2 gene was detected in three patients. A homozygous mutation in ADA2 gene (c.650 T > A; p.Val217Asp) was detected in two siblings. Plasma ADA2 enzymatic activity was absent in all patients. Anti-tumor necrosis factor (TNF) therapy was commenced, and all patients became clinically inactive with normal acute-phase reactants. CONCLUSION:ADA2 mutations should be checked in patients with presence of inflammation and livedoid vasculitis when they have neurological findings, especially in the form of stroke; and a history suggesting for an inherited disease; or presence of resistance to conventional treatment. Besides, anti-TNF seems to be useful for treatment of DADA2.
Entities:
Keywords:
Deficiency of ADA2; Livedo racemosa; Stroke; Vasculitis
Authors: Qing Zhou; Dan Yang; Amanda K Ombrello; Andrey V Zavialov; Camilo Toro; Anton V Zavialov; Deborah L Stone; Jae Jin Chae; Sergio D Rosenzweig; Kevin Bishop; Karyl S Barron; Hye Sun Kuehn; Patrycja Hoffmann; Alejandra Negro; Wanxia L Tsai; Edward W Cowen; Wuhong Pei; Joshua D Milner; Christopher Silvin; Theo Heller; David T Chin; Nicholas J Patronas; John S Barber; Chyi-Chia R Lee; Geryl M Wood; Alexander Ling; Susan J Kelly; David E Kleiner; James C Mullikin; Nancy J Ganson; Heidi H Kong; Sophie Hambleton; Fabio Candotti; Martha M Quezado; Katherine R Calvo; Hawwa Alao; Beverly K Barham; Anne Jones; James F Meschia; Bradford B Worrall; Scott E Kasner; Stephen S Rich; Raphaela Goldbach-Mansky; Mario Abinun; Elizabeth Chalom; Alisa C Gotte; Marilynn Punaro; Virginia Pascual; James W Verbsky; Troy R Torgerson; Nora G Singer; Timothy R Gershon; Seza Ozen; Omer Karadag; Thomas A Fleisher; Elaine F Remmers; Shawn M Burgess; Susan L Moir; Massimo Gadina; Raman Sood; Michael S Hershfield; Manfred Boehm; Daniel L Kastner; Ivona Aksentijevich Journal: N Engl J Med Date: 2014-02-19 Impact factor: 91.245
Authors: Amanda K Ombrello; Jing Qin; Patrycja M Hoffmann; Parag Kumar; Deborah Stone; Anne Jones; Tina Romeo; Beverly Barham; Gineth Pinto-Patarroyo; Camilo Toro; Ariane Soldatos; Qing Zhou; Natalie Deuitch; Ivona Aksentijevich; Sherry L Sheldon; Susan Kelly; Ada Man; Karyl Barron; Michael Hershfield; Willy A Flegel; Daniel L Kastner Journal: N Engl J Med Date: 2019-04-18 Impact factor: 91.245
Authors: Paulina Navon Elkan; Sarah B Pierce; Reeval Segel; Tom Walsh; Judith Barash; Shai Padeh; Abraham Zlotogorski; Yackov Berkun; Joseph J Press; Masha Mukamel; Isabel Voth; Philip J Hashkes; Liora Harel; Vered Hoffer; Eduard Ling; Fatos Yalcinkaya; Ozgur Kasapcopur; Ming K Lee; Rachel E Klevit; Paul Renbaum; Ariella Weinberg-Shukron; Elif F Sener; Barbara Schormair; Sharon Zeligson; Dina Marek-Yagel; Tim M Strom; Mordechai Shohat; Amihood Singer; Alan Rubinow; Elon Pras; Juliane Winkelmann; Mustafa Tekin; Yair Anikster; Mary-Claire King; Ephrat Levy-Lahad Journal: N Engl J Med Date: 2014-02-19 Impact factor: 91.245
Authors: Karyl S Barron; Ivona Aksentijevich; Natalie T Deuitch; Deborah L Stone; Patrycja Hoffmann; Ryan Videgar-Laird; Ariane Soldatos; Jenna Bergerson; Camilo Toro; Cornelia Cudrici; Michele Nehrebecky; Tina Romeo; Anne Jones; Manfred Boehm; Jennifer A Kanakry; Dimana Dimitrova; Katherine R Calvo; Hawwa Alao; Devika Kapuria; Gil Ben-Yakov; Dominique C Pichard; Londa Hathaway; Alessandra Brofferio; Elisa McRae; Natalia Sampaio Moura; Oskar Schnappauf; Sofia Rosenzweig; Theo Heller; Edward W Cowen; Daniel L Kastner; Amanda K Ombrello Journal: Front Immunol Date: 2022-01-10 Impact factor: 7.561
Authors: Oludare A Odumade; Alec L Plotkin; Jensen Pak; Olubukola T Idoko; Matthew A Pettengill; Tobias R Kollmann; Al Ozonoff; Beate Kampmann; Ofer Levy; Kinga K Smolen Journal: Front Immunol Date: 2021-05-27 Impact factor: 7.561